Table 5

ORs with 95% CIs of developing endometrial cancer according to quartiles of levels of compound groups (nmol/g lipid)a

Group of compoundsModelbOR (95% CI)P for trendc
Quartile 1Quartile 2Quartile 3Quartile 4
All PCBsdAge-adjusted1.01.2 (0.6–2.3)1.4 (0.7–2.6)1.5 (0.8–2.8)0.23
Multivariate1.01.1 (0.6–2.2)1.1 (0.6–2.2)1.2 (0.6–2.2)0.72
Estrogenic compounds, not including CB 153eAge-adjusted1.01.4 (0.7–2.7)1.6 (0.8–3.2)1.7 (0.8–3.4)0.15
Multivariate1.01.2 (0.6–2.4)1.2 (0.6–2.4)1.2 (0.6–2.4)0.76
Estrogenic compounds, including CB 153fAge-adjusted1.01.3 (0.7–2.4)1.0 (0.5–2.0)1.2 (0.6–2.4)0.74
Multivariate1.01.1 (0.6–2.1)0.9 (0.4–1.7)1.1 (0.6–2.2)0.90
Antiestrogenic compoundsgAge-adjusted1.01.8 (0.9–3.4)1.7 (0.9–3.4)1.7 (0.8–3.3)0.22
Multivariate1.01.7 (0.9–3.3)1.4 (0.7–2.8)1.5 (0.7–3.0)0.48
Compounds with no known hormonal effect,Age-adjusted1.01.2 (0.6–2.3)1.6 (0.9–3.0)1.6 (0.9–3.1)0.08
including p,p′-DDEhMultivariate1.01.2 (0.6–2.2)1.4 (0.7–2.7)1.3 (0.7–2.4)0.39
Compounds with no known hormonal effect,Age-adjusted1.01.8 (1.0–3.4)1.4 (0.7–2.7)1.3 (0.6–2.5)0.83
excluding p,p′-DDEiMultivariate1.01.9 (1.0–3.6)1.6 (0.8–3.2)1.5 (0.7–3.0)0.47
  • a Including women with levels below the quantification limit (half of the quantification limit was taken as an estimated value).

  • b Multivariate adjusted for age and BMI.

  • c Tests for trend were performed by assigning consecutive integers to levels of categorized variables.

  • d CB 28, CB 52, CB 101, CB 105, CB 118, CB 138, CB 153, CB 156, CB 167, and CB 180.

  • e o,p′-DDT; p,p′-DDT; p,p′-DDD;β -HCH; γ-HCH; trans-nonachlor; oxychlordane; CB 28; CB 52; and CB 101.

  • f o,p′-DDT; p,p′-DDT; p,p′-DDD;β -HCH; γ-HCH; trans-nonachlor; oxychlordane; CB 28; CB 52; CB 101; and CB 153.

  • g CB 105, CB 118, CB 156, and CB 167.

  • h α-HCH, CB 138, CB 180, HCB, and p,p′-DDE.

  • i α-HCH, CB 138, CB 180, and HCB.